Evotec SE has opened its late-stage clinical and commercial biologics cGMP manufacturing facility (J.POD 1 US) in Redmond, Washington.
 
The innovative cGMP biomanufacturing facility is the final step in Just – Evotec Biologics’ J.DESIGN platform that integrates data analytics and machine learning through all activities involved with the discovery, development, and manufacture of biologics. This includes design of discovery libraries, molecules, processes and the manufacturing facility, J.POD.

About the Facility

The facility employs J.POD technology that uses autonomous clean rooms to run small, highly intensified production processes, thereby reducing the cost of biologics manufacturing.

Unique in the industry, the 130,000 square foot J.POD facility was designed with improved environmental sustainability and a dramatically compressed construction time compared to traditional biologics manufacturing. The site includes dedicated quality control and process development laboratories for both clinical and commercial products, a warehouse, and collaborative office and meeting spaces for approximately 200 employees at full capacity.

The innovative “manufacturing ballroom” and clean rooms provide intensified fed-batch or continuous processing up to 1,000 L scale, delivering high quality clinical or commercial grade drug substance from a few kilograms to metric tons.

The facility was built in just 19 months from breaking ground in late 2019, compared to an industry standard of up to 4+ years for a traditional biologics manufacturing facility.
 
A Milestone for the Company

Dr. Werner Lanthaler, chief executive officer of Evotec, commented, “The opening of J.POD 1 US marks a big milestone for our Company and our partners. With this uniquely flexible manufacturing facility, Evotec now has the capabilities in house to not only discover and develop innovative biologics therapies, but also deliver them to the patients who urgently need them. I am very grateful to our Washington-based team at Just – Evotec Biologics who have made this achievement possible right on time – against all odds of the COVID-19 pandemic.”

Dr James Thomas, executive vice president, global head Biotherapeutics for Just – Evotec Biologics added, “The J.POD 1 US facility completes our end-to-end drug discovery and development platform, so we can now partner at every stage of the biologics value chain. This important capability supports our commitment to stand prepared with our leading technology, resources and experience to battle future pandemics if needed.”

Just – Evotec Biologics’ existing Seattle facility, which includes discovery and development labs and an early clinical phase manufacturing plant, will continue to operate as an integral part of Just – Evotec Biologics’ J.DESIGN capabilities.

At its two sites in Washington state, Just – Evotec Biologics currently employs more than 250 highly skilled workers, and is expected to grow to approximately 300 by the end of 2021. The first manufacturing runs for a valued partner, the U.S. Department of Defense, are due to be initiated in November 2021.